Short- and long-interval intracortical inhibition in EPM1 is related to genotype.


Journal

Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R

Informations de publication

Date de publication:
01 2023
Historique:
revised: 15 11 2022
received: 30 06 2022
accepted: 16 11 2022
pubmed: 19 11 2022
medline: 21 1 2023
entrez: 18 11 2022
Statut: ppublish

Résumé

Progressive myoclonic epilepsy type 1 (EPM1) is caused by biallelic alterations in the CSTB gene, most commonly dodecamer repeat expansions. Although transcranial magnetic stimulation (TMS)-induced long-interval intracortical inhibition (LICI) was previously reported to be normal in EPM1, short-interval intracortical inhibition (SICI) was reduced. We explored the association between these measures and the clinical and genetic features in a separate group of patients with EPM1. TMS combined with electromyography was performed under neuronavigation. LICI was induced with an inter-stimulus interval (ISI) of 100 ms, and SICI with ISIs of 2 and 3 ms, and their means (mSICIs) were expressed as the ratio of conditioned to unconditioned stimuli. LICI and mSICI were compared between patients and controls. Nonparametric correlation was used to study the association between inhibition and parameters of clinical severity, including the Unified Myoclonus Rating Scale (UMRS); among patients with EPM1 due to biallelic expansion repeats, also the association with the number of repeats was assessed. The study protocol was completed in 19 patients (15 with biallelic expansion repeats and 4 compound heterozygotes), and 7 healthy, age- and sex-matched control participants. Compared to controls, patients demonstrated significantly less SICI (median mSICI ratio 1.18 vs 0.38; p < .001). Neither LICI nor SICI was associated with parameters of clinical severity. In participants with biallelic repeat expansions, the number of repeats in the more affected allele (greater repeat number [GRN]) correlated with LICI (rho = 0.872; p < .001) and SICI (rho = 0.689; p = .006). Our results strengthen the finding of deranged γ-aminobutyric acid (GABA)ergic inhibition in EPM1. LICI and SICI may have use as markers of GABAergic impairment in future trials of disease-modifying treatment in this condition. Whether a higher number of expansion repeats leads to greater GABAergic impairment warrants further study.

Identifiants

pubmed: 36398398
doi: 10.1111/epi.17466
pmc: PMC10107775
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

208-217

Subventions

Organisme : Wellcome Trust
ID : WT104033AIA
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.

Références

Mov Disord. 2013 Nov;28(13):1860-7
pubmed: 23925991
Epilepsia. 2020 Sep;61(9):1818-1839
pubmed: 32783192
Am J Hum Genet. 1998 Apr;62(4):842-7
pubmed: 9529356
Electroencephalogr Clin Neurophysiol. 1997 Dec;105(6):462-9
pubmed: 9448648
Epilepsy Res. 2010 May;89(2-3):232-7
pubmed: 20117916
Neuroscience. 2021 Jan 1;452:235-246
pubmed: 33246064
Clin Neurophysiol. 2021 Oct;132(10):2464-2472
pubmed: 34454274
PLoS One. 2014 Feb 27;9(2):e89321
pubmed: 24586687
Hum Brain Mapp. 2019 Mar;40(4):1276-1289
pubmed: 30549127
Science. 1996 Mar 22;271(5256):1731-4
pubmed: 8596935
Epilepsia. 2008 Apr;49(4):549-56
pubmed: 18325013
Seizure. 2011 Jan;20(1):65-71
pubmed: 21075014
Epilepsia. 2008 Apr;49(4):557-63
pubmed: 18028412
Clin Neurophysiol. 2015 Oct;126(10):1847-68
pubmed: 25534482
Epilepsia. 2023 Jan;64(1):208-217
pubmed: 36398398
Neuropsychologia. 1977;15(4-5):617-24
pubmed: 896019
Br J Clin Pharmacol. 2022 Jun;88(6):2926-2937
pubmed: 35028950
Epilepsia. 2012 Dec;53(12):2120-7
pubmed: 23205931
Neurology. 2015 Apr 14;84(15):1529-36
pubmed: 25770194
Clin Neurophysiol. 2000 Apr;111(4):624-9
pubmed: 10727913
EMBO Mol Med. 2020 Jun 8;12(6):e11419
pubmed: 32378798
Adv Neurol. 2002;89:361-76
pubmed: 11968461
Clin Neurophysiol. 2015 Jun;126(6):1071-1107
pubmed: 25797650
Exp Brain Res. 2007 Jun;180(2):195-203
pubmed: 17287992
Epilepsy Res. 2013 Sep;106(1-2):103-12
pubmed: 23642573
Clin Neurophysiol. 2008 Oct;119(10):2291-7
pubmed: 18723394
J Physiol. 2006 Sep 15;575(Pt 3):721-6
pubmed: 16809358
Exp Brain Res. 2002 Mar;143(2):240-8
pubmed: 11880900
Neurobiol Dis. 2012 Aug;47(2):216-24
pubmed: 22538221
J Physiol. 1993 Nov;471:501-19
pubmed: 8120818
Clin Neurophysiol. 2008 Jun;119(6):1385-92
pubmed: 18396455
Epilepsia. 2002 Oct;43(10):1149-56
pubmed: 12366728

Auteurs

Katri Silvennoinen (K)

Kuopio Epilepsy Center, Neurocenter, Member of ERN EpiCARE, Kuopio University Hospital, Kuopio, Finland.
Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.
Chalfont Centre for Epilepsy, UK.

Laura Säisänen (L)

Department of Clinical Neurophysiology, Kuopio Epilepsy Center, Neurocenter, Member of ERN EpiCARE, Kuopio University Hospital, Kuopio, Finland.
Department of Applied Physics, University of Eastern Finland, Kuopio, Finland.

Jelena Hyppönen (J)

Department of Clinical Neurophysiology, Kuopio Epilepsy Center, Neurocenter, Member of ERN EpiCARE, Kuopio University Hospital, Kuopio, Finland.

Saara M Rissanen (SM)

Department of Applied Physics, University of Eastern Finland, Kuopio, Finland.

Pasi A Karjalainen (PA)

Department of Applied Physics, University of Eastern Finland, Kuopio, Finland.

Sasha D'Ambrosio (S)

Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.
Dipartimento di Scienze Biomediche e Cliniche "L. Sacco", Università degli Studi di Milano, Milan, Italy.

Diego Jimenez-Jimenez (D)

Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.

Sara Zagaglia (S)

Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.

John C Rothwell (JC)

Sobell Department of Motor Neuroscience and Movement Disorders, UCL Queen Square Institute of Neurology, London, UK.

Simona Balestrini (S)

Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.
Chalfont Centre for Epilepsy, UK.
Neuroscience Department, Member of ERN EpiCARE, Meyer Children Hospital, Florence, Italy.

Sanjay M Sisodiya (SM)

Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.
Chalfont Centre for Epilepsy, UK.

Petro Julkunen (P)

Department of Clinical Neurophysiology, Kuopio Epilepsy Center, Neurocenter, Member of ERN EpiCARE, Kuopio University Hospital, Kuopio, Finland.
Department of Applied Physics, University of Eastern Finland, Kuopio, Finland.

Esa Mervaala (E)

Department of Clinical Neurophysiology, Kuopio Epilepsy Center, Neurocenter, Member of ERN EpiCARE, Kuopio University Hospital, Kuopio, Finland.
Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.

Reetta Kälviäinen (R)

Kuopio Epilepsy Center, Neurocenter, Member of ERN EpiCARE, Kuopio University Hospital, Kuopio, Finland.
Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH